Patents by Inventor Christoph PÖVERLEIN

Christoph PÖVERLEIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR
    Publication number: 20240092819
    Abstract: The present disclosure provides novel piperidine- and guanosine-derived ligands that bind specifically to asialoglycoprotein receptor (ASGPR) and nucleotide analogs conjugated thereto that can be incorporated into oligonucleotides, including double-stranded oligonucleotides such as siRNAs.
    Type: Application
    Filed: October 19, 2021
    Publication date: March 21, 2024
    Inventors: Bettina ELSHORST, Gerhard HESSLER, Armin HOFMEISTER, Ziyu LI, Christoph PÖVERLEIN, Herman SCHREUDER, Gernot ZECH
  • Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 10392366
    Abstract: The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: August 27, 2019
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Christoph Pöverlein, Kurt Ritter, Nis Halland, Matthias Lohmann
  • Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 9908868
    Abstract: The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: March 6, 2018
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 9896434
    Abstract: The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: February 20, 2018
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 9758520
    Abstract: The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: September 12, 2017
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170029405
    Abstract: The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 2, 2015
    Publication date: February 2, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170022198
    Abstract: The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170022182
    Abstract: The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER